Abstract
Patients with Parkinson’s disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.
Keywords: Parkinson's disease, dopamine agonist, PD animal models, neuropathology, biotherapy, atremorine.
Current Medicinal Chemistry
Title:Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease
Volume: 25 Issue: 39
Author(s): Ivan Carrera*, Lucia Fernandez-Novoa, Carolina Sampedro, Vadim V. Tarasov, Gjumrakch Aliev and Ramon Cacabelos
Affiliation:
- Health Biotechnology, EuroEspes Biotechnology, Corunna,Spain
Keywords: Parkinson's disease, dopamine agonist, PD animal models, neuropathology, biotherapy, atremorine.
Abstract: Patients with Parkinson’s disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.
Export Options
About this article
Cite this article as:
Carrera Ivan *, Fernandez-Novoa Lucia , Sampedro Carolina , Tarasov V. Vadim , Aliev Gjumrakch and Cacabelos Ramon , Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease, Current Medicinal Chemistry 2018; 25 (39) . https://dx.doi.org/10.2174/0929867325666180410100559
DOI https://dx.doi.org/10.2174/0929867325666180410100559 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Pharmacogenomics and Personalised Medicine: Consumer Perspectives, Lessons Learned in Australia and Beyond
Current Pharmacogenomics and Personalized Medicine Dysiherbaine: A New Generation of Excitatory Amino Acids of Marine Origin
Central Nervous System Agents in Medicinal Chemistry Exploring the Technology Landscape of 7TMR Drug Signaling Profiling
Current Topics in Medicinal Chemistry Structural Analysis of Relevant Drug Targets for Alzheimer's Disease: Novel Approaches to Drug Development
Current Bioactive Compounds Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Tuberculosis - Present Medication and Therapeutic Prospects
Current Medicinal Chemistry Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Elderly Hypertensive Patients: Silent White Matter Lesions, Blood Pressure Variability, Baroreflex Impairment and Cognitive Deterioration
Current Hypertension Reviews Photoreduction of CO2 into hydrocarbons catalysed by ZnGa2O4/Ga2O3 heterojunction
Current Organic Chemistry Lesions and Dysfunctions of the Nucleus Basalis as Alzheimers Disease Models: General and Critical Overview and Analysis of the Long-Term Changes in Several Excitotoxic Models
Current Alzheimer Research The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Ubiquitin Carboxyl Hydrolase L1 Significance for Human Diseases
Protein & Peptide Letters Current Drug Targets for Antihyperlipidemic Therapy
Mini-Reviews in Medicinal Chemistry The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology Author Index to Volume 1
Current Alzheimer Research Editorial [Hot Topic: Drug Addiction and Brain Targets: From Preclinical Research to Pharmacotherapy (Guest Editor: Shafiqur Rahman)]
CNS & Neurological Disorders - Drug Targets Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial
Current HIV Research Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design DASH Dietary Pattern: A Treatment for Non-communicable Diseases
Current Hypertension Reviews